Suven Secures a Product Patent in Canada | CORPORATE ETHOS

Suven Secures a Product Patent in Canada

By: | April 3, 2018

Apr 3: Hyderabad-based bio-pharma major Suven Life Sciences Ltd on Tuesday announced the grant of one product patent from Canada (2907620) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this Patent is valid through 2033.

According to the company, the granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

Commenting on the development, Venkat Jasti, CEO of Suven, said, “we are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

Suven shares were trading at Rs 172.75, up 0.06% from the previous closing of Rs 172.65, on BSE at 12.30 pm today.